A Randomized, Double-blind, Placebo-controlled, Single Ascending-Dose Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STSA-1201 Injection in Healthy Subjects
Latest Information Update: 10 Apr 2024
At a glance
- Drugs STSA 1201 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Staidson Beijing BioPharmaceuticals
- 03 Apr 2024 Status changed from recruiting to completed.
- 22 Aug 2023 New trial record